LGVN · Longeveron Inc.
$0.74
+0.04 (+6.06%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$23.59M
Shares
31.88M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.74
Open$0.70
Day$0.70–0.75
52W close$0.48–1.16
Avg vol 30d333K
Short int1.6M · 4.9% float · 7.3d
Short vol46%
Last earningsAug 12, 2026
DataMar 2024–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Mar 27, 2024; bars on opposite sides are not compared.
Up next
Next earnings call
Nov 7, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+5%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
38%
mid-range
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+31%
trailing
YTD return
+46%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+23% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.88% of float · ▲ +1.5% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
38 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
−42%
Y/Y
Gross margin
113%
contracting
EPS growth
+51%
Y/Y
Free cash flow
$-18.9M
Balance sheet
$4.4M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2024
annually once fully operational
Contract manufacturing annual revenue
$4M – $5M
annually
Contract manufacturing annual revenue
$4M – $5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
38%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+23% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.88% of float · ▲ +1.5% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
38 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $1 · 38%
Range high $1
vs 200-day avg +2%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LGVN
this stock
Longeveron Inc.
|
$23.59M | +46.2% | -42.0% | — | 4.9% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.16B | +4.1% | +20.8% | 19.8 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Mar 27, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LGVN | -3.4% | +19.0% | +30.7% | +5.5% | +46.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.8% | +14.5% | +17.0% | +1.6% | +32.4% |
Key facts
CIK
1721484
CUSIP
54303L203
13F (30d)
36 filings
36 filers
Visit website
Investor relations